Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.73
+4.2%
$3.57
$2.57
$6.88
$22.12M0.644,371 shs3,252 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.68
+2.4%
$0.82
$0.60
$4.32
$6.05M1.355.38 million shs215,861 shs
Rallybio Corporation stock logo
RLYB
Rallybio
$0.56
-5.0%
$0.47
$0.22
$1.24
$24.64M-1.12444,131 shs263,543 shs
TAOX
Synaptogenix
$6.55
-5.3%
$0.00
$1.84
$11.98
$24.13M1.87276,273 shs189,817 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.45%-10.50%-1.78%+6.55%-36.07%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-2.21%-7.83%-46.49%-3.46%-80.71%
Rallybio Corporation stock logo
RLYB
Rallybio
-1.16%-2.74%+17.07%+84.86%-52.44%
TAOX
Synaptogenix
-0.57%-0.14%+6.13%+691,999,900.00%+691,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.472 of 5 stars
0.04.00.00.03.31.70.6
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
2.7877 of 5 stars
3.54.00.00.03.30.00.6
Rallybio Corporation stock logo
RLYB
Rallybio
3.0186 of 5 stars
3.04.00.00.02.81.71.3
TAOX
Synaptogenix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.00
Buy$12.001,666.26% Upside
Rallybio Corporation stock logo
RLYB
Rallybio
2.00
Hold$5.00792.54% Upside
TAOX
Synaptogenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.20N/AN/A$13.32 per share0.28
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$250K24.78N/AN/A$0.29 per share2.34
Rallybio Corporation stock logo
RLYB
Rallybio
$640K36.58N/AN/A$1.10 per share0.51
TAOX
Synaptogenix
N/AN/AN/AN/A$4.95 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$14.44M-$4.06N/AN/AN/AN/A-214.94%-135.09%11/11/2025 (Estimated)
Rallybio Corporation stock logo
RLYB
Rallybio
-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)
TAOX
Synaptogenix
-$12.77M-$20.16N/AN/AN/A-277.76%-150.79%N/A

Latest PALI, TAOX, RLYB, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
TAOX
Synaptogenix
N/A-$11.26N/A-$11.26N/AN/A
8/11/2025Q2 2025
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.48-$0.58-$0.10-$0.58N/AN/A
8/7/2025Q2 2025
Rallybio Corporation stock logo
RLYB
Rallybio
-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/A
1.62
1.62
Rallybio Corporation stock logo
RLYB
Rallybio
N/A
9.98
9.98
TAOX
Synaptogenix
N/A
20.52
20.52

Institutional Ownership

CompanyInstitutional Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
11.79%
Rallybio Corporation stock logo
RLYB
Rallybio
90.34%
TAOX
Synaptogenix
10.34%

Insider Ownership

CompanyInsider Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
0.65%
Rallybio Corporation stock logo
RLYB
Rallybio
8.70%
TAOX
Synaptogenix
2.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
109.12 million9.06 millionNot Optionable
Rallybio Corporation stock logo
RLYB
Rallybio
4041.79 million38.15 millionNot Optionable
TAOX
Synaptogenix
43.49 million3.39 millionN/A

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.73 +0.15 (+4.19%)
Closing price 04:00 PM Eastern
Extended Trading
$3.81 +0.08 (+2.12%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Palisade Bio stock logo

Palisade Bio NASDAQ:PALI

$0.68 +0.02 (+2.40%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.38%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.56 -0.03 (-5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.57 +0.01 (+1.93%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Synaptogenix NASDAQ:TAOX

$6.55 -0.37 (-5.35%)
As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.